Prospective direct comparison of biologic treatments for severe eosinophilic asthma: Findings from the PRISM study
Annals of Allergy, Asthma & Immunology（2023）
摘要
Three biologics were equally effective as add-on therapy for ESA. Reslizumab may have an advantage in preventing future exacerbation compared to dupilumab. Sputum eosinophils may be a useful consideration when choosing a biological treatment.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要